Press Releases

12.04.2018

The LiMAx® liver capacity test is now commercially available in Germany, Austria and the UK

Berlin, Germany, and Paris, France, April 12, 2018 – Humedics GmbH, a specialist in real-time measurement of individual liver function, today announced that the company has received Marketing Authorization for its diagnostic agent LiMAxetin® in two additional countries: Germany and Austria. LiMAxetin® is the diagnostic agent used to perform the LiMAx® test.

Humedics receives UK Marketing Authorization for its diagnostic agent, LiMAxetin®, and thus achieves full market clearance for the LiMAx® maximum liver capacity test in the UK, - the company’s first in Europe!

The LiMAx® test is now commercially available in the UK

Berlin, Germany, November 21, 2017 – Humedics GmbH, a specialist in real-time measurement of individual liver function at bedside, today announced that the company has received the first Marketing Authorization for its diagnostic agent LiMAxetin®, which is needed to perform the LiMAx® test.

Humedics Announces Appointment of Karsten Damgaard-Iversen as CEO

Reinforcement of senior management team to leverage growth phase of Humedics

Berlin, Germany, May 09, 2017 – The Board of Humedics GmbH is pleased to announce a reinforcement of the senior team of the company with Karsten Damgaard-Iversen (MBA, BScEE), who will take up the role of CEO as of June 1, 2017. Erwin de Buijzer will stay on as managing director (MD) with the title Chief Operations Officer (COO).

Berlin, Germany, November 8, 2016 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that two studies show the potential of the LiMAx test to better assess the eligibility of colorectal cancer patients for liver metastases resection after chemotherapy. The LiMAx test was used to explore the effects of oxaliplatin-based chemotherapy on liver function.

Humedics submits marketing authorization application for the diagnostic agent used with the LiMAx test

Application for marketing authorization of the diagnostic agent 13C-Methacetin Solution for infusion used with the LiMAx test

Berlin, Germany, May 12, 2016 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that the company has submitted the marketing authorization application for the diagnostic agent necessary for the performance of the LiMAx test. The dossier was submitted in Germany, UK and Austria.

Use of LiMAx test leads to reduction in post-hepatectomy liver failure and related mortality

Retrospective analysis of 1170 patients shows improved outcomes of partial liver resections after the determination of the patient’s individual operative risk with the LiMAx test.

Berlin, Germany, January 07, 2016 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced results of a retrospective study investigating the impact of the LiMAx test on clinical patient outcome after hepatectomy. Study results showed that the use of the LiMAx test led to reductions in post-operative liver failure and to a decrease of liver failure related mortality.

Berlin, Germany, September 1, 2015 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced results of a clinical study performed at the RWTH Aachen University Hospital. The aim of the study was to assess alterations in liver function capacity with the LiMAx test after bariatric surgery of obese patients. Study results demonstrated that fatty liver disease is reversible after weight reduction and that the LiMAx test is a reliable tool to measure functional liver recovery after obesity surgery.

Humedics receives ISO 13485 certification

Berlin, Germany, August 10, 2015 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that the company has been certified according to DIN EN ISO 13485. The Quality Management System of the company covers the entire spectrum of processes from design and development, via manufacturing to distribution of its FLIP devices for liver function analysis and corresponding breathing masks. With this certification an important pre-condition for the European marketing of the LiMAx test has been achieved.

Berlin, Germany, December 17, 2014 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that BioMedInvest-II LP complementary joins the Series C financing round now totaling more than 7 million Euro. Humedics’ business model, products and company development has attracted another international investor.

Humedics receives Innovation Award Berlin Brandenburg

Award for LiMAx breath test for liver diagnostics

Berlin, Germany, December 6, 2014 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that the company was awarded with the Innovation Award Berlin Brandenburg 2014. The prize was awarded for the development of the LiMAx test. This breath test allows for the determination of the individual liver function of patients in real time and represents a revolution in functional liver diagnostics.

Improved diagnosis of sepsis-related hepatic dysfunction with the LiMAx test

Prospective study showed superior sensitivity and specificity of the LiMAx test compared to traditional tests and its value as predictor of survival

Berlin, Germany, January 23, 2014 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced the publication of results from a prospective clinical study evaluating the LiMAx test during severe sepsis in comparison with biochemical and indocyanine green tests. Study results demonstrated that the LiMAx test provide an adequate tool to determine early liver dysfunction in sepsis and was found to be a good predictor of survival in septic patients.

Humedics co‐founder Martin Stockmann awarded with Von‐ Langenbeck Prize for the development of the LiMAx test

Award ceremony at the annual conference of the German Society of Surgery

Berlin, Germany, June 10, 2013 – Humedics GmbH, a specialist for real‐time and mobile measurement of the individual liver function at the bedside of the patient, today announced that PD Dr. Martin Stockmann, co‐founder of Humedics and advisor of the management, was awarded with the highest honor of surgery in Germany, the Von‐Langenbeck Prize of the German Society of Surgery (Deutsche Gesellschaft für Chirurgie).

First patients being included directly after study initiation in Berlin and Jena

Berlin, Germany, February 28, 2013 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced the start of a clinical phase III trial. The main goal of this study is the early identification of low-risk patients after partial liver resection by the LiMAx test and improvements in patient management based on test results. After the initiation of first study centers in January, first patients already have been enrolled in Berlin and Jena.

Humedics receives patent on method for quantitative liver function analysis based on a breath test

Patent is a milestone for further commercialization of the LiMAx test

Berlin, Germany, December 5, 2012 ‐ Humedics GmbH, a specialist for real‐time and mobile measurement of the individual liver function at the bedside of the patient, today announced that another key patent protecting Humedics’ proprietary technology has been granted by Australian authorities.

Humedics appoints Erwin de Buijzer as managing director for marketing and sales

Berlin, Germany, May 4, 2012 - Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that Erwin de Buijzer MD MBA has joined Humedics as managing director to support the further development and strategic positioning of the company.

Berlin, Germany, October 10th, 2011 - Humedics GmbH, a specialist for rapid and mobile measurement of the individual liver function at the bedside of the patient, today announced the closing of its first equity financing round. The Charité Biomedical Fund (CBF) managed by Peppermint VenturePartners led this round which included VC Fonds Technologie managed by IBB- Beteiligungsgesellschaft, the ERP Startfonds of the KfW, Ventegis and current investor High-Tech Gründerfonds. The funding enables Humedics to complete the final development and early commercialization of its proprietary and CE-marked diagnostic system to determine the liver function of a patient in real time.